Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

Teresa Peterson, Nathaniel D. Kirkpatrick, Yuhui Huang, +20

Proceedings of the National Academy of Sciences

ImmunologyGbm Patients ReboundHigh-grade GliomasGliomaTumor Biology +14

Targeting CD73 in the tumor microenvironment with MEDI9447

Carl Hay, Erin Sult, Qihui Huang, +15

OncoImmunology

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

Nicolò Rigamonti, Ece Kadioglu, Ioanna Keklikoglou, +3

Cell Reports

Fringe boundaries coincide with Notch-dependent patterning centres in mammals and alter Notch-dependent development in Drosophila

Brenda Cohen, Arash Bashirullah, Lina Dagnino, +12

Nature Genetics

BiologyNotch-dependent DevelopmentPattern FormationDevelopmental BiologyFringe Boundaries +8

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Jonathan Rios‐Doria, Nicholas M. Durham, Leslie Wetzel, +6

Neoplasia

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding, Víctor Moreno, Yung‐Jue Bang, +16

Clinical Cancer Research

Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation

Xi-De Wang, Ching Ching Leow, Jiping Zha, +6

Developmental Biology

Lineage PlasticityDevelopmental BiologySignal TransductionSignaling PathwayCell Regulation +6

Hath1, Down-Regulated in Colon Adenocarcinomas, Inhibits Proliferation and Tumorigenesis of Colon Cancer Cells

Ching Ching Leow, Maria S. Romero, Sarajane Ross, +2

Cancer Research

PathologyGoblet CellsCancer BiologyTumor BiologySignaling Pathway +14

Angiopoietin 2 regulates the transformation and integrity of lymphatic endothelial cell junctions

Wei Zheng, Harri Nurmi, Sila Appak‐Baskoy, +12

Genes & Development

Ang2 InhibitionCellular PhysiologyInflammationAngiogenesisTissue Development +16

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Matthew D. Hellmann, Nicoletta Bivi, Boris Calderón, +13

Clinical Cancer Research